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Abstrakt:  
Mnoho protinádorových cílených terapií má za následek neinvazivní bolesti kloubů, artralgii. 
Mechanismus signalizace bolesti v artralgii není zcela pochopen, ale mnoho studií vede k závěru, že 
zánětlivé cytokiny hrají důležitou roli v artralgii. Zvláště interleukin (IL)-6 byl detekován ve vysokých 
hladinách plazmatického séra pacientů léčených terapií anti-vaskulárním endoteliálním růstovým 
faktorem (anti-VEGF). I když se zdá, že IL-6 je klíčovým faktorem způsobujícím artralgii, byly 
popsány i další možné mechanismy. Tento článek poskytuje přehled známých informací o vztahu 
cytokinů a bolesti kloubů. Udává také návrhy možné léčby a budoucího směřování výzkumu 
léčebných postupů. 
 





Many targeted anti-tumor therapies result in arthralgia, the non-inflammatory joint pain. The 
mechanism of pain signaling in arthralgia is not entirely understood but many studies lead to a 
conclusion that inflammatory cytokines play an important role. Especially interleukin (IL)-6 has been 
detected in high levels in plasma of patients treated with anti-vascular endothelial growth factor (anti-
VEGF) therapy. Although IL-6 seems to be the key factor causing arthralgia, other possible 
mechanisms have been described. This review focuses on the published data about the correlation 
between cytokines and cancer-related arthralgia. Possible treatments and future directions are also 
described. 
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1. Introduction  
Cancer refers to the large group of diseases caused by abnormal cell growth, division and 
invasiveness. It is the leading cause of death worldwide. In 2015 cancer took about 8.8 million lives, a 
number corresponding to one in every six deaths globally. The total of new cancer cases is expected to 
rise by 70 % in the two upcoming decades. The World Health Organization reported that up to 50 % of 
cancer cases could have been prevented if current preventative recommendations were followed.   
Over the last 50 years, scientists have been intensively trying to find an effective cure; the 
anti-angiogenic factor therapy belongs to the most successful ones. Even though other new therapies 
appear to be highly efficient and significantly improve treatment results as well, high-grade toxicity 
can force patients to retreat from the therapy. 
This thesis will deal with the topic of arthralgia and its possible triggers and mechanisms. 
Arthralgia is a non-inflammatory pain of joints. Many cancer patients suffer from this problem during 
their cancer treatment. Vascular endothelial growth factor (VEGF) plays a major role in the 
pathophysiology of joint pain and therefore, anti-VEGF therapies are in particular associated with this 
complication. VEGF also plays an important role in osteoarthritis (OA). Studies of arthritic processes 
provide important information on arthralgia associated with anti-VEGF therapy. The important 
characteristics of OA are the degeneration and breakdown of cartilage in contrast to arthralgia 
associated with anti-cancer therapies. 
The most crucial cytokines involved in arthralgia will be identified and their effects described 
and compared with inflammatory arthritis. Additionally, this paper will summarize the formation 
about dysregulation of the mentioned cytokines during the VEGF treatment. 
This literature review will compile known information and provide an overview of arthralgia 
discussing future directions of research and treatment, although there are not many clinical studies 
presenting clear data about arthralgia and its etiology because of the very complex interaction of 
immunomodulatory cytokines.  
2. Arthralgia  
2.1. Definition and incidence 
Arthralgia is defined as joint pain, stiffness or aching in the joints. It is an off-target toxicity of 
therapies targeted at cancer. It has a non-destructive impact on cartilage and articular capsule. 
Arthralgia can be also described as a joint pain with non-inflammatory condition, unlike arthritis, that 
is inflammatory (Hardin 1990). In contrast to arthralgia related to cancer treatment, OA results in bone 
and cartilage degeneration and loss (Maroudas 1976; Bonnet & Walsh 2005; Spector et al. 1997). 




abundantly during aromatase inhibitor treatment, in therapy with certain chemotherapy agents such as 
taxanes, and during some viral infections. Alasker et al. published a review on toxicities of targeted 
therapies of metastatic renal cell carcinoma and the prevalence of arthralgia in axitinib treated cohort 
was 15 %. For sunitinib arthralgia occurred at 11 % of all patients and for sorafenib treatment at 10 % 
(Alasker et al. 2013). These rates include all grade symptoms (See Figure 1. below). 
 
 
Figure 1. The grading system (1-5) of arthralgia and arthritis according to the Common Terminology Criteria for Adverse Events 
(CTCAE). 
Modified and taken from (CTCAE, 2009). 
 
There are a few researches pointing out the importance of focusing on arthralgia and its cure. 
A study of women with arthralgia symptoms after inhibitor intake shows, that a severe pain (4 grade of 
severity) often leads to discontinuation of the treatment before planned time (Chim et al. 2013). Any 
discontinuation or interrupted treatment increases the mortality rate and worsens the outcome of the 
therapy (Hershman et al. 2012). 
Several cytokines in the pathophysiology of arthralgia have been identified in relation to 
autoimmune disorders, infections and cancer treatment, including granulocyte macrophage colony 
stimulating factor (GM-CSF), interleukin 6 (IL-6), interleukin 4 (IL-4), interleukin 10 (IL-10) and 
Tumor necrosis factor alpha (TNF-α). 
2.2. Mediators of arthralgia associated with cancer therapies 
2.2.1. Vascular endothelial growth factor 
Angiogenesis is defined as the formation of blood vessels from the existing ones. It is a 
process crucial for development and growth of a tumor larger than 1mm3. Bigger tumors lacks enough 
oxygen and by hypoxia inducible factor (HIF) upregulates production of VEGF, the factor promoting 
angiogenesis. TNF-α activates  nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
which then stimulates production of HIF-α (van Uden et al. 2008). VEGF promotor contains hypoxic 
response element (HRE) where the HIF-α binds and initiates the transcription of VEGF (Vinores et al. 




VEGF is a specific mitogen for endothelial cells. This protein stimulates neovascularization 
and plays a significant role in angiogenesis (Kelly 2005). Although angiogenesis is a complex process 
that requires a gradual activation of some tyrosine kinase receptors (e.g. TIE1, TIE2), VEGF is the 
major rate determining factor of its progression (Jeltsch et al. 2013). VEGF is the signaling molecule 
for oxygen supply mechanism and it is expressed by many adult organs and various cell types such as 
macrophages and monocytes  (Leung et al. 1989; Berse et al. 1992).  
The VEGF family includes VEGF-A, -B, -C, - D, -E, -F and a placental growth factor (PlGH). 
Their receptors are tyrosine kinases (see Figure 2). The way in which the angiogenetic signal is 
transduced to the cell depends on the type of the VEGF receptor involved (VEGF-1,-2, 3, NRP-1,-2) 
(Leung et al. 1989). VEGF family proteins are homodimers except for VEGF-A and PlGH that have 
been isolated in heterodimeric forms (DiSalvo et al. 1995; Cao et al. 1996). 
 
 
Figure 2. The Family of VEGF Molecules and Receptors Taken from (Kerbel, 2008). 
Both environmental and genetic factors induce VEGF expression. VEGF-A isoforms are 
are crucial mediators of tumor angiogenesis and the angiogenic signal is transduced  
through the VEGF receptor 2. 
 
 In the study published by Kim et al., VEGF inhibitors were injected to a rat with an 
aggressive type of cancer and the growth of tumor decreased rapidly (Kim et al. 1993). The rate of 
tumor growth was directly proportional to the effect of VEGF inhibition, resulting in greater tumor 
regression in response to the growth factor inhibition. This study demonstrated that VEGF-induced 
angiogenesis supports the growth of tumor.  
The importance of the VEGF treatment, especially in renal carcinoma, is significant because 




chemotherapy (Rini et al., 2009). Consequently, many studies were looking into the von Hippel-
Lindau (VHL) gene function and its influence on VEGF receptor. VHL is a tumor suppressor located 
on the short arm of chromosome 3 (3p26–p25). Mutation of the VHL gene is the most common 
genetic change causing clear-cell renal cell carcinoma (ccRCC). In the sporadic ccRCC the incidence 
of VHL mutation reaches up to 91 %. The somatic mutations are either missense mutations appearing 
in 32 % of cases or frameshift and nonsense mutations accounting for 55 % of all mutations (Gossage 
et al. 2015). The VHL mutation results in the excessive production of VEGF. VEGF not only 
promotes angiogenesis but also prevents endothelial apoptosis, induces expression of anti-apoptotic 
proteins in endothelial cells and arrests the development of dendritic cells, promoting tumor growth 
and allowing it to escape from the immune system (Rini et al. 2011; Cowey & Rathmell 2009). 
Several studies have suggested that VEGF could be the plasma biomarker of anti-angiogenic cancer 
treatment. An example of this is an analysis of VEGF levels in patients treated with sunitinib. The 
levels of VEGF were 2.2 fold higher after 2 weeks of  treatment, then fell to the baseline values and 
repeatedly increased with the subsequent cycles (Norden-Zfoni et al. 2007). Nevertheless, evaluation 
of VEGF levels has never been validated for use in clinical practice.  
Aside from its role in angiogenesis, VEGF is also neuropathic factor stimulating the growth of 
dorsal root ganglion (DRG) axons (Sondell et al. 2000). Pelletier et al. explain, the neurotropic ability 
of VEGF in their study (Pelletier et al. 2015). New blood vessels can support the creation of new 
nerves and then the inflammation in a synovial joint causes pressure, which leads to a development of 
painful sensation through them. The innervation angiogenesis brings new nerves to aneural cartilage 
and that will also cause pain during movement. The innervation of the cartilage and neovascularization 
is the main cause of pain in OA and therefore anti-VEGF antibodies are the best candidates for the  
therapy targeting this disorder. Some researchers have proposed that this mechanism could also 
contribute to arthralgia. It has been reported that treatment with antibody against VEGF is beneficial 
for patients with osteochondral defects. Inhibiting the activity of this growth factor contributed to the 
cartilage repair (Nagai et al. 2014).  
Interestingly, cartilage damage in OA is not always associated with joint pain and the severity 
of OA does not correlate with the intensity of pain (Davis et al. 1992). Cartilage is an aneural tissue 
and cannot transduce pain. Normal joint nociceptors have a high threshold for pain so that the 
everyday movements do not hurt. Some scientists believe that if the damage does not determine the 
pain grade then it also does not cause pain by itself. Rather, the pain is mediated by inflammatory 
cytokines and the same cytokines can activated pain pathway in the absence of cartilage damage, 
causing  arthralgia (Dieppe & Lohmander 2005). In a study on OA patients treated with hyaluronic 
acid and dermatan sulphate it was shown that the joint pain was attenuated by the oral medication and 
cytokine levels changed correspondingly. Final concentrations were observed to decrease compared to 




supporting the theory that these proteins play  a role in thee transduction of joint pain (Nelson et al. 
2015). 
The anti-angiogenic inhibitors bind to the VEGFs and block them from binding to their 
receptors, preventing formation of new blood vessel and enabling cartilage repair (Nagai et al. 2008). 
Bevacizumab as explained by a study Nagai et al., binds to VEGF but does not change or inhibit its 
expression and the concentration of VEGF measured in the synovium fluid remained stable in a study 
of OA patients (Nagai et al. 2014). 
Although VEGF plays a role in cartilage damage in inflammatory arthropathies, in certain 
situations joint pain can be induced by anti-VEGF or anti-vascular endothelial growth factor receptor 
(VEGFR) treatment (Langenberg et al. 2011; Garcia et al. 2008). When VEGF-A isoforms bind to 
VEGFR2, this receptor directly promotes nociception of neurons (Hulse et al. 2014). DRG neurons 
express VEGFR2 and its inhibition sensitizes the neurons. Also, VEGF-A165b isoform is known to be 
neuroprotective, hence anti-VEGF therapy might block the neuroprotective properties and cause 
neuropathic pain (Verheyen et al. 2012; Verheyen et al. 2013; Beazley-Long et al. 2013). The balance 
between isoforms appears to be important and Hulse et al. clarify this, with results of a study on mice. 
High concentration of VEGF-A165a isoform in the microenvironment of sensory neurons intensifies 
pain perception through VEGFR2. Five minutes after detected action potential in the peripheral 
neurons with administrated VEGF-A165a, the neurons had lowered activation threshold and became 
sensitive to mechanical stimuli. The isoform b attenuates the effects of isoform a, therefore, the 
isoform VEGF-A165b is a promising molecule for applications in analgesic therapy (Hulse et al. 2014). 
A relationship between VEGF and IL-6, another key mediator of arthralgia, has been 
suggested. Anti VEGF therapy combined with anti-IL-6 therapy is key to abrogate proliferation of 
cancer cells and invasion of residual cancer cells into the rest of the body. Due to the fact that VEGF 
synthetized by the glioblastoma cells induced IL-6 and the IL-6 upregulated VEGF using STAT3 
factor activation, both proteins pathways overlap and are essential for the tumor growth. The 
combined knock-down of both pathways resulted in lowered or almost completely inhibited synthesis 
of VEGF and IL-6 proteins (Angelo & Kurzrock, 2007; Saidi et al., 2009). 
2.2.2. C-reactive protein 
The study of Limper et al. demonstrated that patients suffering from arthralgia have activated 
acute-phase response to some extent because they have higher hsCRP levels compared to healthy 
controls. In the cases where arthralgia progressed into arthritis, the amount of IL-6 and IL-10 cytokine 
escalated (Limper et al. 2012). These results suggest that CRP can be a part in a signaling pathway 
leading to arthralgia.  
It is widely known that CRP represents an immune response of a body to the tumor growth. 




can stimulate production of some cytokines like TNF-α, IL-6 and vice versa (Castell et al. 1990). 
Decreasing levels of CRP usually coincide with improvement of arthralgia (Thummala et al. 2015). 
 
2.2.3. Tumor necrosis factor-alpha 
The regulation of immune cells and inflammation in the body is largely mediated by a factor 
TNF-α. As it includes the whole immune system, TNF-α must be produced by many cell types within 
the body. Macrophages are the major site of TNF- α expression and in reaction to tumor cells, TNF- α 
is released from the Golgi complex (Shurety et al. 2000). Both “pro” and “anti” tumor activity were 
described in TNF-α (Balkwill 2006). It can induce apoptosis and inflammatory mediators by binding 
to tumor necrosis factor receptor 1 (TNFR1) (Varfolomeev & Ashkenazi 2004). Tumors and their  
microenvironment can produce this cytokine in low and high amounts respectively (Li et al. 2009; 
Carswell et al. 1975).  
Anti-TNF agents such as the chimeric monoclonal antibody infliximab are commonly used in 
targeted therapies for autoimmune diseases. Many scientists assumed that the alleviation of arthralgia 
during the course of anti-TNF therapy was caused by the suppression of inflammation. Boettger et al. 
brought a new perspective by testing whether the inhibition of TNF-α has a direct effect on neurons. 
The results proved to be right. The mechanical hyperalgesia faded but the inflammation of joint 
persisted (Boettger et al. 2008). 
TNF-α can act directly on nociceptors and change the receptor potential to elicit transduction 
of pain signal. The depolarization of peripheral terminals can be achieved by regulation of ion 
channels. TNF-α affects its receptors TNFR1 and TNFR2 but the pain behavior seems to be dependent 
on activation of only one subtype, the TNFR1 that is expressed by sensory neurons. In a mice model 
study, the knockout of TNFR2 did not reduce hyperalgesia (Sommer et al. 1998).    
Deswal et al. found out, that lower levels of estrogen in the postmenopausal women increase 
the cytokine (TNF-α, IL-6, IL-1) secretion (Bismar et al. 1995; Deswal et al. 2001). The production of 
TNF-α also depends on BMI and on the amount of adipose tissue in the body (Hotamisligil et al. 
1995).  
Lastly, TNF-α induces the expression of transient receptor potential vanilloid 1(TRPV1) gene 
through factor-κB and hypoxia-inducible factor. That might also be a contribution to pain signaling 
through DRG neurons (Hatano et al. 2012). 
Corticosteroids are frequently used in the treatment of arthralgia related to systemic 
inflammatory conditions. They inhibit certain cytokines including TNF-α, thus suggesting that TNF-α 
could participate in arthralgia aggravation (Lovato et al. 2016). 
     2.2.4. GM-CSF 
GM-CSF stimulates maturation and proliferation of macrophages, which secrete other 




Chikungunya virus (CHIKV). 60 % of the CHIKV cohort had increased levels of GM-CF (Chow et al. 
2011). The other high cytokine levels observed were IL-6, IL-4, IL-10 and TNF-α suggesting that 
cooperation of more cytokines lead to long-lasting and reoccurring arthralgia after the onset of the 
virus infection (Chirathaworn et al. 2013; Santiago et al. 2015; Tappe et al. 2017). 
Schiller et al. reported 24 % incidence or arthralgias and myalgias during the study of 3-hour 
paclitaxel infusion delivered to patients with untreatable malignancies. The paclitaxel administration 
was divided into “with” and “without” granulocyte-colony stimulating factor (G-CSF). Authors of this 
study suggest that the augmentation of arthralgia and myalgia toxicity is related to infusion with G-
CSF because it appeared after the infusion. Particularly the arthralgias repeatedly occurred 1 or 2 days 
after drug administration and ceased within 6 days (Schiller et al. 2017). 
     2.2.5. Substance P 
Another molecule of interest is substance P (SP), a neurotransmitter that is upregulated in 
some cancers, including colorectal cancer (CRC). This highly expressed mediator, was identified in 
retinaculum, fat pad, periosteum, and subchondral plate and these findings were also associated with 
increased expression of its receptor NK1R (Wojtys et al. 1990). A recent article written by Chen et al. 
maintains that the CRC promotes greater secretion of SP which acts as a marker for the cancer 
progression. Elevated amount of SP occurred in 68,5 % of patients. Increased concentration correlated 
with poorer outcome and worse survival rate (Chen et al. 2016). The naturally occurring ingredient of 
chili pepper, capsaicin, activates its receptor TRPV1 by binding to it and causes substance P depletion 
from sensory neurons (Jessell et al. 1978). The activation also leads to calcium influx that results in a 
release of certain neuropeptides. This whole release process affects epithelial and immune cells  and 
causes them to produce for example IL-6 and TNF-α (Holzer 1988). In 2011 an article emerged 
proposing a theory that mitigated pain could be a result of neuronal loss of function (Anand & Bley 
2011). In the naturally occurring situation, TRPV1 can cause temporary depolarization after being 
activated through heat, acidosis or antagonists. By binding an exogenous agonist such as capsaicin, 
that is chemically a stable molecule, the effects becomes permanent and the neuronal endings collapse 
because of calcium overload and loss of membrane potential in mitochondria. After repeated 
application of capsaicin the neurons became nearly immune against mechanical and thermal 





Figure 3. Simplified mechanism of capsaicin induced pain and defunctionalization. Taken from (Anand & Bley 2011). 
     2.2.6. Vitamin D  
Studies on postmenopausal women treated with aromatase-inhibitor (AI) for breast cancer 
state that arthralgia correlates with measured amount of 25-hydroxyvitamin D (25-OHD). Although 
the results have not been unambiguous, several studies have reported a correlation between vitamin D 
levels and arthralgia. Insufficient amount or deficiency of 25-OHD (less than 10 ng/ml) caused 
arthralgia in 34,7  % of the patients. Much lower proportion of non-destructive and non-inflammatory 
pain (15 %) was identified within the cohort with 25-OHD level above 30 ng/ml.  Later, with rising 
level of 25-OHD in the serum, the intensity of pain decreased. The authors of this study concluded that 
arthralgia is undoubtedly related to vitamin D levels (Heidari et al. 2013). The severity of pain was 
associated with  25-OHD deficiency because the lowest levels presented the highest severity of 
arthralgia (Servitja et al. 2015). 
Garcia-Giralt et al. analyzed results of women treated with AI between the years 2006-2012, 
where approximately half of the patients reported worsening of arthralgia. CYP17A1, CYP27B1, 
and VDR genes were identified to have strong association with arthralgia (Garcia-Giralt et al. 2013). 
Genetic variants of these genes, that enable vitamin D activation, exhibit risk of AI-related arthralgia. 
Furthermore, future determination of specific single nucleotide polymorphisms within the mentioned 
genes could be highly beneficial for prevention of arthralgia and assessing the most convenient 
treatment of postmenopausal breast cancer patients.  
     2.2.7. IL-6 
IL-6 is a pleiotropic cytokine that was first recognized as a factor inducing a production of 
immunoglobulins by B lymphocytes. Later it was discovered that it is also one of the myokines 
produced by myocytes in a reaction to muscle contractions (Pedersen & Febbraio 2008). It also causes 
cells such as T-cells or plasmacytoma and myeloma cells to proliferate and differentiate. IL-6 enables 




release of hormones such as prolactin or luteinizing and growth hormone (Umeguki et al. 1996; Taga, 
Tetsuya 1997). Although IL-6 is characterized as a pro-inflammatory cytokine, there have been 
numerous studies published reporting on the evidence of its anti-inflammatory effects. 
With the induction of tocilizumab (IL-6 receptor inhibitor) the level of IL-6 increases and 
researchers suggest that the increase may affect the development of non-inflammatory joint pain. After 
the first administered dose of tocilizumab antibody, 36,7 % of all patients developed arthralgia of large 
joints and the level of IL-6 rose significantly compared to healthy controls without arthralgia. The 29 
subjects suffering from large joint pains were in the cohort with rheumatoid arthritis (RA). The newly 
developed pain started a day after tocilizumab injection and usually lasted for a week. It originated in 
different joints than the ones affected by RA and there were no other signs of RA (Uda & Saiki 2013). 
Increased levels of IL-6 are thought to cause arthralgia in some viral diseases. Levels of 
cytokines in serum of patients with Chikungunya fever caused by the CHIKV were monitored and 
especially IL-6 and IL-8 were abnormally higher. In patients reporting persistent joint pain2-3 months 
after the onset of the illness, the concentration of IL-6 in the serum was much higher compared to 
patients with no persistent arthralgia (Chow et al. 2011).  
Another Japanese study provided data that show how IL-6 influences patient’s inflammatory 
conditions, in this case, patients with cutaneous polyarteritis nodosa (CPN). Out of 45 subjects 
observed and examined nineteen people, 42,2 % had elevated IL-6 levels in the blood serum. More 
importantly, 32 people suffered from arthralgia (71,1 %) and from the group of patients with elevated 
IL-6, 94,7 % experienced arthralgia. CRP and TNF-α concentrations were also elevated. In the group 
of subjects with normal levels of IL-6 in the serum, arthralgia occurred only in 53,8 % of the cases. 
Overall, the incidence of non-inflammatory joint pain was higher in the group of people with higher 
IL-6 levels (Kawakami et al. 2012).  
Apart from all the attempts to detect the link between arthralgia and specific cytokine, some 
studies on rats already focus on the possible ways of how certain interleukins cause and promote the 
joint pain or pain in general. IL-6 receptor family all comprise glycoprotein 130 (gp130) and this 
common feature is found in all DRG neurons. Segond von Banchet et al. suggest DGR neurons 
express the IL-6 receptor (Segond von Banchet et al. 2005). Gp130 is a main transducing unit in the 
receptor signaling, possibly pain signaling, to neurons. Long-term exposure to IL-6 led to increase 
number of neurons that were able to react to substance P by enhancing the expression of neurokinin 1 
receptor (NK1R) that is activated by the substance P. On top of that, several published studies state 
that IL-6 promotes mechanical hypersensitivity and heat hypersensitivity (Obreja et al. 2002; Quarta et 
al. 2011). 
Brenn et al. suggested specific IL-6 pain signaling in group C nerve fibers. Firstly, the 
injection of IL-6 and its soluble receptor evoked rapid sensitization. The co-administration of soluble 
gp130, that neutralizes IL-6, prevented C-fibers sensitization. These results also depended on the dose 




To summarize all the results from the mentioned studies, IL-6 is a key cytokine for arthralgia. 
Its role is very important because it can elicit non-inflammatory joint pain even without combining the 
effects of other suspected cytokines like TNF-α or IL-4 (Siebert et al. 2007). This cytokine has been 
mainly known for causing inflammatory pain, but all collected evidence is proving that IL-6 exerts 
either direct effect or influences the signaling cascade leading to arthralgia. In addition, IL-6 can act as 
a predictive biomarker for metastatic renal cell carcinoma (Negrier et al. 2004). Overall survival as 
well as the progression free survival is worsened by the elevated IL-6 in serum after the bevacizumab 
chemotherapy (Hara et al. 2017).  
     2.2.8. IL-10 
IL-10 was first described in the 1989 as a factor inhibiting production of T helper 1 (Th1) cells 
cytokines (Fiorentino et al. 1989). This immunomodulatory cytokine is produced not only by 
monocytes and lymphocytes, but also by tumor cells such as colon carcinoma, renal cell carcinoma 
and neuroblastoma cells (Gastl et al. 1993).  As the research from Terai et al. explains, IL-10 is 
produced by melanoma cells as well, but only in the presence of IL-6 in the medium. The exact 
mechanism remains unclear but the obtained data lead to the conclusion that blocking the JAK 
signaling pathway (inhibition of STAT3 or ERK1/2 phosphorylation) represses the production of IL-
10, therefore, it increases the tumor resistance against therapy (Terai et al. 2012). 
IL-10 is able to activate macrophages that would induce tumor angiogenesis. The polarization 
of macrophage in the presence of IL-4 and IL-10 cytokine enhances production of IL-10 in high 
concentrations. The macrophages stimulated this way will, later on, become pro-angiogenic and the 
ones without IL-10 will inhibit the creation of new vessels (Dace et al. 2008; Apte et al. 2006). 
     2.2.9. IL-4  
This pleiotropic cytokine stimulates activation and differentiation of B cells, initiates 
differentiation of T cells and acts on many other cell types. Macrophages are alternatively activated by 
IL-4. IL-4 is upregulated in many cancer types and can also induce proliferation, growth or 
reoccurrence of cancer (Chang et al. 2015; Roca et al. 2012; Prokopchuk et al. 2005). IL-4 receptor 
(IL-4R) blockade inhibits metastasis in some types of cancer (Hosoyama et al. 2011).  
IL-4, when used as experimental therapy in cancer patients, is well tolerated and significantly 
reduces production of inflammatory cytokines (Maher et al. 1991). The occurrence of arthralgia, as a 
side effect, was observed in 21 % of patients in a study on efficacy of the administrated IL-4 
to chronic lymphocytic leukemia cohort. Together with fatigue, arthralgia seems to be dose related in 




3. Antineoplastic therapies associated with arthralgia 
3.1. Anti-VEGF agents 
Anti-VEGF therapy targets VEGF or its receptor, blocking angiogenesis and tumor growth. 
Many anti-VEGF medications have good efficacy in treatment of primary tumors. On the other hand, 
some cases reported reduced survival and accelerated metastasis (Ebos et al. 2009).  
     3.1.1. Monoclonal antibodies 
As already mentioned, Bevacizumab (trade name Avastin) is a monoclonal antibody best 
known for its anti-angiogenic properties. It has been approved for the use in European Union since 
2005 and metastatic colon cancer is one of the most frequently bevacizumab-treated cancers (EPAR 
,2009). 
Some of the conducted studies on this medication show results that clearly prove that 
combination of chemotherapy with bevacizumab enhances the effect of the treatment. The levels of 
IL-6 drastically decreased compared to patients receiving chemotherapy alone already after the first 
round of bevacizumab administration. It also increased the T-cell counts in peripheral blood. This 
treatment prolongs the progression free time and rises survival rates in metastatic melanoma cohort 
(Mansfield et al. 2013).   
 3.1.2. Antibody derivates  
Antibody derivates include drugs such as ranibizumab which is a fragment developed from 
Bevacizumab often used for treating  macular degeneration. Some articles doubt the cost-effectiveness 
of the derivate and suggest replacing the treatment with Bevacizumab instead (Stein et al. 2014).   
Aflibercept is also known under the name VEGF-trap and is one of the drugs used to treat 
metastatic colorectal cancer. It is a recombinant fusion protein comprising three domains from 
VEGFR1and a constant portion of human immunoglobulin G. Aflibercept treatment causes all grade 






Figure 4.The inhibition mechanism of tegorafenib, aflibercept and bevacizumab. Taken from (Ciombor et al. 2013). 
3.1.3. Orally-available tyrosine kinase inhibitors 
For example very frequently used sunitinib, pazopanib, lapatinib, sorafenib, axitinib belong to 
this category. 
Sunitinib is widely used for treating metastatic renal cell carcinoma (RCC). Treatment by this 
medication can elevate the levels of IL-6 by more than 100 % (Motzer et al. 2007).  Porta et al. 
observed this elevation in 37,3 % of patients in the sunitinib efficacy study (Porta et al. 2013). Harmon 
et al. provide proof not only for the reduction of tumor growth, but also suggest for the prediction 
value of low levels of VEGF receptor 3, which can be used as a biomarker for outcome of sunitinib 
treatment (Harmon et al. 2014). 
Another kinase inhibitor drug sorafenib is known to cause arthralgia to the treated patients 
(Guidetti et al. 2014). The treatment also causes enhancement of IL-4 and IL-6 levels detected in the 
plasma. 44 % of patients with metastatic renal cell carcinoma  had these concentrations elevated 
(Zurita et al. 2012). 
      3.1.4. Adverse effects of anti-VEGF therapy 
Anti-VEGF therapy may be administered using diverse group of antibodies such as sunitinib, 
sorafenib, pazopanib, bevacizumab, paclitaxel and aflibercept. As VEGF inhibitors, these antibodies 
are used to stop or slow down angiogenesis and neovascularization. Many side effects and toxicities 
appear after treatment with currently available antibodies, but the severity varies. The severity can be 
resolved by lowering the dosage, postponing or even interrupting the treatment. Interrupted treatment 




The side effects of the VEGF-inhibitor treatment can be divided into following: general 
symptoms, cardiovascular toxicities, skin toxicities, gastrointestinal symptoms and arthralgia 
(Schmidinger 2013).  
Cancer-related fatigue (CRF) is the most common toxicity caused most frequently by 
sunitinib. Especially in breast cancer, patients experience CRF even years after successful treatment. 
Newest research suggests prescribing supervised exercise that significantly reduces this side effect 
(Meneses-echávez et al. 2015).  Arthralgia and CRF are usually appearing together during 
chemotherapy. These symptoms are strongly related and both correlate with CRP and vitamin D–
binding protein levels in patients (Bauml et al. 2015) 
The complete mechanism of fatigue is not known yet but a few hypotheses already exist and 
due to the severity of the side-effect and its affect on patient´s lives there are a lot of studies in 
progress to solve this issue. There have been investigations going on since the1990s focusing on the 
inflammation hypothesis indicating that IL-1β and TNF-α promote fatigue by sending signals to the 
brain from peripheral immune system (Meyers et al. 2005). Certain psychological factors such as 
stress and biological factors including modulation by pro-inflammatory cytokines and inflammation 
participate in the CRF mechanism (Bower 2014). The changes in IL-6 during chemotherapy might 
also have an impact on the CRF (Liu et al. 2012).   
Other reported toxicities listed as “general symptoms” are asthenia, weight loss or myalgia and 
depression. Hemorrhage has also been associated with the usage of VEGF inhibitors. As VEGF 
inhibitors (VEGFI) interrupt the signaling function of this endothelial factor, it interferes with fast and 
effective healing of wounds and also restricts capillaries renewal, therefore causing bleedings 
(Scappaticci et al. 2005; Schmidinger 2013). All these general symptoms are interconnected and may 
aggravate each other.  
High arterial pressure is one of the most common side effects that appear after introducing the 
anti-VEGF therapy and many clinical trials reported high occurrence of hypertension in treated 
patients (Mittal et al. 2014; Girardi et al. 2010). Hypertension, as well as some other treatment-related 
adverse events (palmar-plantar erythrodysesthesia and general symptoms) were noticed mainly after 
the sunitinib usage, but none of it reached 4 grade of severity in research (Motzer et al. 2009).  
Cellular nitric oxide is a pulmonary vasodilator and blocked VEGFR2 reduces the release of 
the oxide in arterial smooth muscle cells therefore it is a possible cause for arterial hypertension during 
cancer treatment (Tang et al. 2004; Fan et al. 2014). 
Left ventricular dysfunction is another quite frequently occurring type of cardiotoxicity and it 
is caused by tyrosine-kinase inhibitors as well as monoclonal antibodies (Yeh & Bickford 2009; 
Bordun et al. 2015). 
The occurrence of thromboembolic effect was increased after anti-VEGF treatment, especially 
after Bevacizumab (anti-VEGF monoclonal antibody), sorafenib and sunitinib (tyrosine kinase 




increases the incidence of arterial thromboembolism by 2,1 % (Scappaticci et al. 2007). There are 
many pathways leading to thrombotic event but anti-VEGF treatment removes the essential 
component of maintaining homeostasis and dealing with coagulation cascade (Shord et al. 2009). 
The most reported arterial thrombotic events associated with cancer treatment by anti-
angiogenic treatment are cerebrovascular accidents and myocardial infarction. Although the incidence 
is 1% it can become lethal for diabetic patients who are at high risk for cardiovascular complications 
(Coutinho et al. 1999). According to the analyzed data from 1950 to 2012,  VEGF inhibitors increase 
the likelihood of arterial thrombotic events (Faruque et al. 2014). Nalluri et al. meta-analysis shows 
data claiming that the incidence of venous thrombotic events can rise up to 19 % (Nalluri et al. 2015). 
These events include deep venous thrombosis, pulmonary embolism, mesenteric venous 
thrombosis, and axillary venous thrombosis (Faruque et al. 2014; Thulliez et al. 2014). 
Palmar-plantar erythrodysesthesia, also called the hand-foot syndrome (HFS) is one of the 
most common side effects of the sunitinib treatment together with others like hypertension, fatigue, 
and diarrhea. In the research comparing sunitinib and interferon alpha (IFN-α), these toxicities 
developed more in the sunitinib cohort but did not reach grade 4 of severity (Motzer et al. 2009). 
According to Columbia et al. the incidence of HFS in sunitinib studies is 30 % (Columbia et al. 2011). 
Endothelial repair and survival abilities are impaired by the treatment and highly-pressured areas on 
soles and palms lack the competency to repair in time, therefore, remain damaged until reaching the 
common HFS characteristics.  
Hair or skin depigmentation, dry skin, alopecia and rash can also occur during the anti-VEGF 
treatment but not many researchers determined the direct link between the treatment and the toxicity 
(Schmidinger 2013). Some skin toxicities such as acneiform of skin rash develop in 90 % of patients 
receiving cetuximab and panitumumab medications (Saif et al. 2008). 
As the anti-VEGF treatment suppresses angiogenesis and neovascularization, the inadequate 
blood supply results in weakening the walls of bowel. The gastrointestinal tract cannot hold the 
pressure of incoming food and perforates. Another research proposed that perforation can occur after 
bowel damage with disabled wound healing (Han & Monk 2007). The risk of bowel perforation is 
very low (up to 1,5 %) and depends mostly on the type of cancer  but it is the most lethal (21,7 %) side 
effect among the mentioned ones (Hapani et al. 2009; Shord et al. 2009; Hainsworth et al. 2004). 
3.2. mTOR inhibitors 
Everolimus is a derivate of rapamycin blocking mechanistic target of rapamycin (mTOR) 
kinase. It has antiproliferative effect on some type of cancers. Everolimus is also used for 
immunosuppression after transplantations. The treatment-induced arthralgia is resolved by reduction 




3.3. Microtubule inhibitors 
Paclitaxel (trade name Taxol) is a drug targeting tubulin in the cell. It belongs to taxane 
medication group which causes up to 90 % of neuropathy cases (including arthralgia) among the 
taxane treated patients (Imai et al. 2012). Ripamonti et al. found out that pathologies such as myalgia 
and arthralgia have prevalence of up to 20% in Taxol treated patients (Ripamonti et al. 2014). 
Paclitaxel treatment increases plasma levels of IL-6 and IL-10, but this increase is schedule-dependent. 
The same study explains that IL-10 levels strongly correlated with joint pain reported by the patients 
and their weekly doses of paclitaxel (Pusztai et al. 2004). 
3.4. Aromatase inhibitor  
Arthralgia and joint stiffness are very common toxicities for breast cancer survivors and can 
last many years after the disease onset. The etiology of arthralgia in breast cancer is thought to be 
related to abrogation of estrogen synthesis or function which is commonly employed as a part of 
treatment of hormone-positive breast cancer.  Crew et al. reported a 50 % incidence of arthralgia 
among postmenopausal women receiving aromatase inhibitor (AI) treatment for breast cancer (Crew et 
al. 2007). Considering the fact that breast cancer is one of the leading causes of deaths among women, 
arthralgia influences the quality of life of a large part of the population (Parkin et al. 2005).  The 
relation between arthralgia and AI cancer treatment is still unknown but some analyses confirm the 
correlation with low levels and level drops of estrogen usually observed in perimenopausal women 
(Ho et al. 1999). Surprisingly the linkage between estrogen levels and arthralgia was discovered 
already in 1925 (Cecil & Archer 1925). Estrogen depletion could be the cause of higher sensitization 
of nociceptors in the joint, however this theory has not been proven and only few researches support it 
(Dawson-basoa & Gintzler 1993). Moreover, according to some researches, the levels of certain 
cytokines such as IL-6 and TNF-α are increased by diminishing estrogen (Rachon et al. 2002; Zheng 
et al. 1997). 
Aromatase, coded by CYP19A1 gene, is an enzyme synthetizing estrogen. The mechanism of 
aromatase inhibition therapy is based on inhibition of the last step of biosynthesis when the enzyme is 
converting androstenedione to estrone and testosterone to estradion (Bulun et al. 2004). Further 
research detected 8 alleged polymorphism in the CYP19A1 gene lowering the risk of arthralgia. On 
the other hand, the haplotype M_3_5 of CYP19A1 gene is increases that risk (Mao et al. 2011; Park et 
al. 2011). Although there is a limited number of articles focused on this specific topic and Garcia-
Giralt et al. did not manage to prove this theory in their own study (only associated SNP rs4775936 
with worsening pain), all results should be considered because they might match with future research 
and play pivotal role in understanding the exact mechanism of joint pain (Garcia-Giralt et al. 2013). 
Several tissues produce estrogen but the most important source in postmenopausal woman is 
the adipose tissue due to the decrease in the ovarian production. Therefore, it has been hypothesized 




supporting evidence for this theory. Body mass index (BMI) affects the estrone and estradiol levels in 
human body (Folkerd et al. 2012). Higher levels were detected with higher BMI making aromatase 
inhibition treatment less effective (Decker et al. 2014). The estrogen resides more in the secondary 
tissues producing estrogen therefore the aromatase inhibition appears to be less effective. Five out of 
eight studies in a systematic review of Ioannides et al., presented that higher BMI resulted in worse 
breast cancer outcome (Ioannides et al. 2014). Thus, weight reduction could not only lead to 
amelioration of arthralgia but also to improvement in cancer survival in hormone-positive breast 
cancer patients. 
4. Emerging treatments for arthralgia associated with cancer 
treatment 
Due to the fact that the mechanism of arthralgia has not yet been fully clarified, there are only 
a few studies and clinical trials describing a treatment that reduces joint pain.  Bee venom from species 
Apis mellifera was used for acupuncture on rats with induced spinal cord injury. The damaged tissue 
expressed high levels of pro-inflammatory cytokines such as IL-6 and TNF-α. After the injection of 
venom to the acupoints the IL-6 levels dropped (Nascimento de Souza et al. 2017). Also, a Chinese 
study detected the same cytokine levels decrease after warm acupuncture treatment (Cai et al. 2014). 
There are more cases of recent trials of acupuncture that lowered the concentration of IL-6, TNF-α 
(Wang et al. 2016). All these studies have similar results that include the decline in cytokine 
concentrations. In addition, Chen et al. confirmed that the acupuncture has positive effects on AI-
induced arthralgia (Chen et al. 2017). These novel results, however, need to be verified in further 
clinical trials.  
TRPV1 is a capsaicin-sensitive ion-channel that gives a rise to pain. Gp130 is important for 
TRPV1 expression and transmission of pain signals. An experiment on mice with gp130 knock-out 
showed that the mice were less sensitive to mechanical stimuli and the expression of TRPV1 was 
much lower in the DRG neurons compared to control mice (Malsch et al. 2014). Gp130 is an IL-6 
family receptor subunit that also plays an important role in maintaining hypersensitivity to mechanical 
stimuli (Quarta et al. 2011). Theoretically, blocking this receptor would preclude arthralgia 
development despite the high levels in the plasma serum. Tocilizumab and siltuximab are already used 
anti-IL-6 targeted medications but the available literature on their use for arthralgia  is still limited 
(Baldo 2016; Deroux et al. 2016). The effects of these drugs seem to be based on the suppression of 
the macrophage activation syndrome (MAS). The central factor seems to be IL-10. The suppression of 
IL-10 leads to a dysregulation of the cytokine net and creation of the “cytokine storm” (Schulert & 
Grom 2014; Behrens et al. 2011). 
In addition, tocilizumab was successfully used in a treatment for multicentric Castleman’s 




pathophysiology of this rare disorder. After 8 weeks of treatment, the joint pain subsided together 
with other symptoms (Oshima et al. 2017).  
 Currently, there is not enough information on how to interconnect all the cytokines into one 
pathological model. Hence, it is unclear how to select patients for anti-IL-6 therapy. 
5. Conclusion  
IL-6, IL-10, TNF-α, GM-CSF and many other inflammatory cytokines appear at high 
concentrations in peripheral blood of cancer patients with induced targeted chemotherapy. The 
complex interactions of the cytokine net also make it very hard to describe single pathways and their 
outcomes. IL-6 seems to highly correlate with the occurrence of arthralgia but IL-4, IL-10 and TNF-α 
also contribute to the overall outcome. Despite their inflammatory characteristics, new theories arose 
suggesting that these proteins could have a great significance in induction of non-inflammatory pain. 
The pain signal seems to be transduced through the IL-6 receptor and therefore, IL-6 antagonist or 
inhibitor of its receptor appears as great candidate to effectively attenuate the pathology. 
In order to find the optimal treatment, we need to know more about the arthralgia itself. 
Further research on the selected cytokines must be conducted to elucidate their non-inflammatory, 
pain signaling properties. Based on that, the mechanism will be better understood and medication can 
specifically target the major contributors in the arthralgia signaling pathway. 
Lastly, it would be convenient to induce the chemotherapy locally so that we can minimize the 
side effects of whole-system treatment. It would significantly improve the overall outcome if we could 
optimize and more importantly personalize the cancer treatment. That could be the best way to 
eliminate unwanted adverse effects and stop the cancer cells from proliferating while allowing for 
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